Cancer Research AACR Conference on Molecular Diagnostics - 2008  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 921-925, April 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segal, A.
Right arrow Articles by Melchionne, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segal, A.
Right arrow Articles by Melchionne, S.

Tumor-promoting Activity of 2,3-Dihydrophorbol Myristate Acetate and Phorbolol Myristate Acetate in Mouse Skin1

A. Segal, B. L. Van Duuren, U. Maté, J. J. Solomon, I. Seidman, A. Smith and S. Melchionne

Laboratory of Organic Chemistry and Carcinogenesis, Institute of Environmental Medicine, New York University Medical Center, New York, New York 10016

Phorbolol myristate acetate (PHMA) had been previously prepared from the potent mouse skin tumor promoter phorbol myristate acetate (PMA) by sodium borohydride reduction of the C-5 carbonyl group in PMA to a secondary alcohol. PHMA was shown to have an inflammatory effect in mouse skin equal to that of PMA. 2,3-Dihydrophorbol myristate acetate (DPMA), a new compound, was prepared from the 3-aldehyde of PMA by catalytic hydrogenation. DPMA exhibited no detectable inflammatory effect in mouse skin. Both DPMA and PHMA were tested on the dorsal skins of female ICR/Ha Swiss mice (30/group) for 433 and 380 days, respectively, in separate experiments. The tumor-promoting activity of both compounds was reduced significantly, compared with that of equimolar doses of PMA. For each treatment the number of mice with tumors per total number of tumors was: DPMA, 9/17; PMA, 29/553 at 10 µg/mouse; PMA, 30/317; PHMA, 24/69 at 2.5 µg/mouse. The results suggest that specific binding requirements influence the tumor-promoting and hyperplastic activity of PMA and its closely related derivatives in mouse skin.

1 This research was supported by USPHS Grants CA 15095, CA 13343, and ES 00260.

Received 9/23/77. Accepted 1/ 4/78.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. S. Iordanov and B. E. Magun
Loss of Cellular K+ Mimics Ribotoxic Stress. INHIBITION OF PROTEIN SYNTHESIS AND ACTIVATION OF THE STRESS KINASES SEK1/MKK4, STRESS-ACTIVATED PROTEIN KINASE/c-Jun NH2-TERMINAL KINASE 1, AND p38/HOG1 BY PALYTOXIN
J. Biol. Chem., February 6, 1998; 273(6): 3528 - 3534.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.